WISH, Feasibility of a Factorial Design

NCT ID: NCT07023822

Last Updated: 2025-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-16

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to evaluate the feasibility of testing a multi-component intervention for sexual function using a factorial design.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This proposal builds upon a multi-component pilot study (WISH), where women with a history of breast cancer participated in a two-component intervention to improve vulvovaginal atrophy with a vaginal moisturizer and sexual desire and body image with Hypnotic Relaxation (HR), a mind-body intervention that includes suggestions for relaxation, improved sexual desire, and body image delivered via audio file. This study seeks to further test WISH by expanding vulvovaginal atrophy interventions to include either a polycarbophil-based vaginal moisturizer (Replens™) or a hyaluronic acid-based moisturizer (HYALO GYN ®); and hypnosis relaxation (HR) or progressive muscle relaxation (PMR) interventions for sexual desire and body image. The primary outcome is the feasibility of a multi-component intervention for sexual function using a factorial design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Vulvovaginal Signs and Symptoms Sexual Desire Disorder Body Image

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

This is a feasibility of a factorial design testing a multi-component intervention to improve vulvovaginal atrophy, sexual desire and body image. The investigators will also explore effect sizes of the chosen outcome measures to gather preliminary efficacy data.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyaluronic acid (HLA) Vaginal Moisturizer + Hypnosis

Participants will use an HLA vaginal moisturizer every 3 days, weeks 1-8.

Participants will listen to hypnotic relaxation audio files at least 3x/week, weeks 3-8. There are 3 audio files in total, each about 20 min in length. The files are listened to in order. Each file is used for 2 weeks.

Group Type EXPERIMENTAL

Hyaluronic acid (HLA) Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Hypnotic Relaxation

Intervention Type BEHAVIORAL

Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.

Hyaluronic acid (HLA) Vaginal Moisturizer + PMR

Participants will use an HLA vaginal moisturizer every 3 days, weeks 1-8.

Participants will listen to a progressive muscle relaxation (PMR) audio file at least 3x/week, weeks 3-8. There is only 1 PMR audio file. The same file will be used for 6 weeks.

Group Type EXPERIMENTAL

Hyaluronic acid (HLA) Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Progressive Muscle Relaxation (PMR)

Intervention Type BEHAVIORAL

Listen to PMR audio file at least 3x/week for weeks 3-8.

Hyaluronic acid (HLA) Vaginal Moisturizer Only

Participants will use an HLA vaginal moisturizer every 3 days, weeks 1-8.

Group Type EXPERIMENTAL

Hyaluronic acid (HLA) Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Polycarbophil Vaginal Moisturizer + Hypnosis

Participants will use a polycarbophil vaginal moisturizer every 3 days, weeks 1-8.

Participants will listen to hypnotic relaxation audio files at least 3x/week, weeks 3-8. There are 3 audio files in total, each about 20 min in length. The files are listened to in order. Each file is used for 2 weeks.

Group Type EXPERIMENTAL

Polycarbophil Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Hypnotic Relaxation

Intervention Type BEHAVIORAL

Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.

Polycarbophil Vaginal Moisturizer + PMR

Participants will use a polycarbophil vaginal moisturizer every 3 days, weeks 1-8.

Participants will listen to a progressive muscle relaxation (PMR) audio file at least 3x/week, weeks 3-8. There is only 1 PMR audio file. The same file will be used for 6 weeks.

Group Type EXPERIMENTAL

Polycarbophil Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Progressive Muscle Relaxation (PMR)

Intervention Type BEHAVIORAL

Listen to PMR audio file at least 3x/week for weeks 3-8.

Polycarbophil Vaginal Moisturizer Only

Participants will use a polycarbophil vaginal moisturizer every 3 days, weeks 1-8.

Group Type EXPERIMENTAL

Polycarbophil Vaginal Moisturizer

Intervention Type DEVICE

Use of vaginal moisturizer every 3 days for weeks 1-8.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronic acid (HLA) Vaginal Moisturizer

Use of vaginal moisturizer every 3 days for weeks 1-8.

Intervention Type DEVICE

Polycarbophil Vaginal Moisturizer

Use of vaginal moisturizer every 3 days for weeks 1-8.

Intervention Type DEVICE

Hypnotic Relaxation

Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.

Intervention Type BEHAVIORAL

Progressive Muscle Relaxation (PMR)

Listen to PMR audio file at least 3x/week for weeks 3-8.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 female
2. Ability to read and write English
3. History of any stage of breast cancer
4. Completed primary treatment (chemotherapy, radiation and/or surgery) ≥3 months and ≤ 10 years prior to registration. Participants may use concurrent adjuvant endocrine therapy or HER2-targeted therapy while on study.
5. Able to engage in sexual activity including penetration or insertion into the vagina
6. Currently has a sexual partner.
7. Responds "yes" to "Do you currently experience vaginal or vulvar dryness and/or discomfort/pain with sexual activity?"
8. Responds "yes" to at least one of the following questions:

* "Have you experienced negative changes in your body image since being diagnosed or treated for cancer?" or
* "Have you experienced negative changes in your sexual desire since being diagnosed or treated for cancer?"

Exclusion Criteria

1. Antidepressants are allowed if a person has been on them for 30 days prior to registration, and dose or treatment is not expected to change.
2. An active psychiatric disorder that is or causing you symptoms or distress, such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, PTSD, schizophrenia or borderline personality disorder (Defined per medical history and/or patient self-report)
3. Currently enrolled in another study that addresses sexual health (enrollment in other clinical trials will be allowed).
4. Previous participant in WISH Study
5. Currently receiving active treatment
6. Use of oral, transdermal or vaginal estrogen
7. Allergy or intolerance to Replens, Hyalo Gyn or any of their components.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Breast Cancer Research Foundation

OTHER

Sponsor Role collaborator

The University of Tennessee, Knoxville

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Noel M Arrign, DNP, PhD, RN

Role: PRINCIPAL_INVESTIGATOR

College of Nursing, University of Tennessee

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Tennessee, College of Nursing

Knoxville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UTK IRB-25-08813-XP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Awareness Enhancing Interventions
NCT04683510 COMPLETED NA
Nurse Intervention Project
NCT01091584 COMPLETED NA
Psychosexual Educational Partners Program (PEPP)
NCT06253182 ACTIVE_NOT_RECRUITING NA
Strategies to Promote Skin Health
NCT03237013 COMPLETED NA